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Table 1. Effects of Rifaximin onmarkers of inflammation andT
cell activation
Biomarker 1
Control
Mean (SE)
Treatment
Mean (SE)
Absolute
Treatment
Effects Mean
(95% CI)2
Relative
Treatment
Effect3 P value
IL-6 (pg/ml)
Baseline 0.98 (0.45) 2.55 (0.48)
Day 0 3.14 (0.51) 2.16 (0.51) -1.01 (-1.61, -0.41) 0.36 0.002
Day 15 10.58 (0.61) 8.35 (0.63) -0.89 (-1.98, 0.19) 0.41 0.10
sTNFR1 (pg/ml)
Baseline 1811 (1102) 1442 (1112)
Day 0 2243 (2243) 2097 (2097) 0.16 (-0.15, 0.47) 1.17 0.16
Day 15 3532 (3532) 3197 (1089) 0.13 (-0.21, 0.47) 1.15 0.45
sIL2R (ng/ml)
Baseline 5.35 (1.20) 3.54 (1.22)
Day 15 12.89 (1.25) 14.24 (1.27) 0.51 (-0.29, 1.31) 1.67 0.20
1Geometric means and standard errors, calculated by exponentiating
Poster Session II S309patients undergoing allogeneic SCT were included in this study.
Peripheral blood samples were taken prior to transplant and weekly
until day +100. To assess if Th17 cells are involved in cGVHD,
further samples were taken at 6 months and 1 year. Peripheral
blood mononuclear cells were stimulated with PMA/Ionomycin
and the lymphocytes were assessed for the intracellular expression
of IL-17 and IL-22. In parallel, plasma was analysed for IL-17 pro-
duction.
We found the frequency of IL-17 and IL-22 producing cells was
no higher in the 21 patients with aGVHD than the 16 patients
without GVHD either at the onset of, or one week prior to
aGVHD onset. Accordingly, the concentration of IL-17 in the
plasma did not differ between the two groups. IL-17 producing
cells and plasma levels were not elevated in patients who developed
cGVHD. To exclude that circulating Th17 cells were not identi-
fied because of marginalization from the blood into tissues, we iso-
lated T cells from the skin of patients with aGVHD (n5 5) and
cGVHD (n5 7) and tested them for their capacity to produce
Th17 associated cytokines. Interestingly, in patients with either
acute or chronic GVHD, we found a population of cells that pro-
duced IL-22 but not IL-17 or IFN-g. In accordance with this find-
ing, the expression of CCR6, a marker for Th17 cells, was
significantly lower in patients with GVHD. Our findings suggest
that in humans, Th17 do not appear to contribute to the patho-
physiology of GVHD, however in keeping with recent reports,
there appears to be a distinct IL-22 producing population that
may be important in skin pathology.the mean of the log transformed values.2Absolute treatment effect is
the absolute change from baseline to follow-up in the treatment group
minus the absolute change in the control group from the mixed effects
model. 3Relative treatment effect is defined as: (treatment group follow-
up/treatment group baseline)/(Placebo group follow-up/Placebo group
baseline). The interpretation of the relative effect is similar to that of
the odds ratio.412
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Bacterial translocation across damaged gut mucosa is critical in
the pathogenesis of acute graft versus host disease (AGVHD).
Pre-clinical research has demonstrated that mitigating the effects
of gut flora prevents AGVHD. Rifaximin is a broad acting, mini-
mally absorbed oral antibiotic, which has been shown to be effec-
tive in inflammatory bowel disease. We conducted a pilot trial to
test the hypothesis that rifaximin would abrogate systemic inflam-
mation and resultant T cell activation in allogeneic transplant re-
cipients. Twenty adult and pediatric ($12 years) allogeneic blood
and marrow transplant recipients who received myeloablative con-
ditioning were enrolled. Rifaximin (400 mg bid) was started on day
-10 and continued through day 30. Enzyme-linked immunosorbent
assays were performed on plasma samples at baseline, day 0 (pre-
transplant) and day 15 to measure levels of markers of inflamma-
tion, soluble TNF receptor 1 (sTNFR1) and interleukin 6 (IL-6),
and donor T cell activation, soluble IL-2 receptor (sIL-2R). A his-
torical control group (n5 24) was formed from subjects enrolled
on a previously conducted study. There were no significant differ-
ences between the 2 groups in conditioning regimen, proportion of
alternative donors or GVHD prophylaxis. The treatment group
was significantly younger (median age 17.3 vs. 38.8 years) and in-
cluded significantly more cord blood transplants (7 (3 single unit
and 4 double unit) vs. 0). The mean percentage of rifaximin doses
successfully administered was 86.2%. There were no serious ad-
verse events attributed to rifaximin. The incidences of grade 2-4
AGVHD, grade 3-4 AGVHD and stage 1-4 gastrointestinal
AGVHD were similar between the 2 groups (treatment vs. control:
69% vs. 58% p5 0.63, 34% vs. 22% p5 0.50 and 58% vs. 45%
p5 0.58, respectively). Mean IL-6 concentration decreased by
64% in the treatment group relative to the control group by day
0 (p5 0.002) (table 1). At day 15, the relative change was 59%
(p5 0.1). sTNFR1 and sIL-2R did not change in the treatment
group relative to the control group. Controlling for age and donor
did not alter the results. This pilot study demonstrates that admin-
istering rifaximin to prevent AGVHD is safe and feasible. Rifaxi-
min appears to limit inflammation stemming from bacterialtranslocation as suggested by its effect on IL-6 levels, but its
anti-inflammatory effect is insufficient to prevent activation of
donor T cells; therefore, it may not be suitable for GVHD
prophylaxis.413
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In animal models, regulatory T cells (Treg) have been demon-
strated to control autoimmune inflammation and prevent acute
graft versus host disease (AGVHD), but the role of Treg in
chronic GVHD (CGVHD) remains unknown. In a natural history
study of CGVHD patients (NCI 04-C-0281), we assessed the fre-
quency and phenotype of FoxP3 + T cells in blood and in affected
tissues. We used immunofluorescent staining for FoxP3 and con-
focal microscopy to assess Treg in tissue biopsies from patients
with oral and lichenoid cutaneous CGVHD. Although no sequen-
tial biopsies were examined, the consistent observation was that
the number of FoxP3+ cells was increased in severely affected
oral mucosa and lichenoid skin compared to clinically uninvolved
tissue, but remained in proportion to the total CD3 + T cell pop-
ulation. Using multiparameter flow cytometry, we determined that
the frequency of FoxP3+ cells among circulating CD4 + T cells did
not differ in CGVHD patients compared to normal donors, al-
though the absolute numbers of total CD4 and Treg were lower
than normal. We assessed the origins of Treg cells after transplan-
tation by comparing the frequency of naive (CCR7 + CD45RA+),
thymic-matured ‘natural’ Treg and peripherally expanding (Ki-
67+) Treg. The decline in the frequency of naive CD4 T-cells in
CGHVD patients was more severe in FoxP3 + CD4 than in
FoxP3- CD4 (106 2% vs 276 3%; P\0.00001), whereas the fre-
quency of cells in cycle was increased in FoxP3 + CD4 cells (196 2
vs 76 1%, P\0.00001). This result is consistent with a greater
impact of transplantation and CGVHD on thymic-dependent gen-
eration of Treg than of FoxP3- CD4 cells and a concomitant
increase in proliferative expansion. These data suggest that Treg
populations can recover to frequencies proportional to total
CD4 cells in CGVHD patients and can move into inflamed tis-
sues, but that reconstitution is primarily by peripheral expansion
rather than thymopoiesis.
